Clifford Capital Partners’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-409,669
| Closed | -$16.7M | – | 51 |
|
|
2024
Q3 | $16.7M | Buy |
409,669
+51,378
| +14% | +$2.1M | 3.34% | 12 |
|
|
2024
Q2 | $13.8M | Buy |
358,291
+63,033
| +21% | +$2.43M | 3% | 20 |
|
|
2024
Q1 | $12.7M | Buy |
295,258
+8,046
| +3% | +$345K | 3.21% | 15 |
|
|
2023
Q4 | $10.6M | Buy |
287,212
+6,971
| +2% | +$258K | 2.75% | 21 |
|
|
2023
Q3 | $10.2M | Buy |
280,241
+13,934
| +5% | +$505K | 2.96% | 20 |
|
|
2023
Q2 | $9.49M | Sell |
266,307
-448
| -0.2% | -$16K | 2.75% | 19 |
|
|
2023
Q1 | $9.49M | Buy |
266,755
+4,788
| +2% | +$170K | 2.92% | 20 |
|
|
2022
Q4 | $9.21M | Buy |
261,967
+59,641
| +29% | +$2.1M | 2.8% | 22 |
|
|
2022
Q3 | $5.95M | Buy |
202,326
+390
| +0.2% | +$11.5K | 2.55% | 20 |
|
|
2022
Q2 | $11.2M | Buy |
201,936
+73,482
| +57% | +$4.07M | 4.47% | 3 |
|
|
2022
Q1 | $6.99M | Buy |
128,454
+37,361
| +41% | +$2.03M | 3.77% | 8 |
|
|
2021
Q4 | $5.02M | Buy |
91,093
+16,305
| +22% | +$899K | 3.75% | 9 |
|
|
2021
Q3 | $3.57M | Buy |
74,788
+4,639
| +7% | +$222K | 3.27% | 14 |
|
|
2021
Q2 | $3.49M | Buy |
70,149
+3,915
| +6% | +$195K | 3.27% | 13 |
|
|
2021
Q1 | $2.96M | Sell |
66,234
-108,020
| -62% | -$4.82M | 3.07% | 15 |
|
|
2020
Q4 | $8.02M | Buy |
174,254
+33,305
| +24% | +$1.53M | 3.14% | 16 |
|
|
2020
Q3 | $6.63M | Buy |
140,949
+38,018
| +37% | +$1.79M | 3.21% | 17 |
|
|
2020
Q2 | $5.25M | Buy |
102,931
+441
| +0.4% | +$22.5K | 2.71% | 23 |
|
|
2020
Q1 | $4.85M | Sell |
102,490
-466
| -0.5% | -$22.1K | 3.13% | 17 |
|
|
2019
Q4 | $6.05M | Sell |
102,956
-526
| -0.5% | -$30.9K | 2.77% | 23 |
|
|
2019
Q3 | $5.52M | Buy |
103,482
+356
| +0.3% | +$19K | 2.66% | 22 |
|
|
2019
Q2 | $5.16M | Buy |
+103,126
| New | +$5.16M | 2.49% | 26 |
|